Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
PD-L1 amplification
i
Other names:
PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
29126
Related biomarkers:
Expression
Mutation
CNA
Others
‹
PD-L1 elevation (15)
TMB-H + PD-L1 expression (15)
EGFR mutation + PD-L1 overexpression (8)
TMB-H + PD-L1 overexpression (7)
EGFR exon 19 deletion + PD-L1 overexpression (5)
EGFR mutation + PD-L1 expression (5)
KRAS G12C + PD-L1 overexpression (4)
KRAS mutation + PD-L1 expression (4)
MSI-H/dMMR + PD-L1 expression (4)
PD-L1 expression + EGFR mutation (4)
CD74-ROS1 F2004L + PD-L1 expression (3)
EGFR wild-type + ALK wild-type + PD-L1 expression (3)
MSI-H/dMMR + TMB-H + PD-L1 negative (3)
PD-L1 expression + TMB-H (3)
PD-L1 overexpression + KRAS mutation (3)
ALK rearrangement + PD-L1 overepxression (2)
BRAF V600E + PD-L1 expression (2)
BRAF V600E + PD-L1 expression (2)
EGFR L858R + PD-L1 overexpression (2)
EGFR exon 19 deletion + PD-L1 expression (2)
HER-2 amplification + PD-L1 expression (2)
KRAS G12C + PD-L1 underexpression (2)
KRAS mutation + PD-L1 negative (2)
MSI-H/dMMR + TMB-H + PD-L1 overexpression (2)
PD-1-L + PD-L1 elevation (2)
PD-L1 expression + NRAS Q61R + BRAF D594N (2)
PD-L1 expression + TMB-H + FANCA deletion (2)
PD-L1 overexpression + BRAF V600E (2)
PD-L1 overexpression + EGFR mutation (2)
PD-L1 overexpression + FGFR3 amplification (2)
PD-L1 overexpression + MET exon 14 mutation (2)
RAD51B promoter methylation + PD-L1 expression (2)
TMB-H + PD-L1 negative (2)
TMB-H + PD-L1 underexpression (2)
TMB-L + PD-L1 expression (2)
ALK wild-type + NT5E overexpression + PD-L1 expression (1)
ALK-EML4_V3a + PD-L1 overexpression (1)
ALK-EML4_V3b + PD-L1 overexpression (1)
BAP1 R300Gfs*6 + PD-L1 expression (1)
BAP1 deletion + TMB-L + PD-L1 expression (1)
BRAF E501Q + PD-L1 negative (1)
BRAF V600 + LDH elevation + PD-L1 negative (1)
BRAF mutation + PD-L1 overexpression (1)
BRCA1 mutation + PD-L1 expression (1)
CDKN2A mutation + PD-L1 overexpression (1)
Chr del(9p) + PD-L1 overexpression (1)
DDR + PD-L1 expression (1)
EGFR G719A + EGFR S768I + PD-L1 overexpression (1)
EGFR G719A + PD-L1 overexpression (1)
EGFR L747P + PD-L1 overexpression (1)
EGFR L858R + PD-L1 expression (1)
EGFR L858R + PD-L1 underexpression (1)
EGFR P719A + PD-L1 overexpression (1)
EGFR V843I + KRAS G13D + AKT1 E17K + PD-L1 overexpression (1)
EGFR exon 19 deletion + EGFR T790M + PD-L1 expression (1)
EGFR exon 19 deletion + PD-L1 underexpression (1)
EGFR exon 20 insertion + PD-L1 overexpression (1)
EGFR fusion + PD-L1 overexpression (1)
EGFR mutation + PD-L1 elevation (1)
EGFR mutation + PD-L1 expression + TP53 mutation (1)
EGFR mutation + PD-L1 negative (1)
EGFR negative + ALK negative + PD-L1 expression (1)
EGFR wild-type + ALK wild-type + NT5E overexpression + PD-L1 expression (1)
FGFR mutation + PD-L1 expression (1)
HER-2 exon 20 insertion + TMB-L + PD-L1 negative (1)
HLA-A*02 + PD-L1 expression (1)
HLA-A*02:01 + PD-L1 expression (1)
HRAS Q61R + TP53 P278S + PD-L1 overexpression (1)
KEAP1 mutation + TMB-H + PD-L1 overexpression (1)
KMT2C mutation + BCOR mutation + KDM5C mutation + PD-L1 expression (1)
KRAS G12C + PD-L1 expression (1)
KRAS G12C + PD-L1 underexpression + STK11 mutation (1)
KRAS mutation + PTPN11 overexpression + PD-L1 overexpression (1)
KRAS mutation + PD-L1 underexpression (1)
KRAS mutation + TP53 mutation + PD-L1 expression + PD-1 expression (1)
LDHA-L + PD-L1 expression (1)
LDHB-L + PD-L1 expression (1)
MET exon 14 mutation + MET amplification + PD-L1 overexpression (1)
MGAM mutation + PD-L1 overexpression (1)
PAPPA2 mutation + PD-L1 expression (1)
PD-L1 amplification + CD3D overexpression (1)
PD-L1 amplification + HLA-DRA overexpression (1)
PD-L1 amplification + LAG3 overexpression (1)
PD-L1 amplification + PD-L2 amplification + TMB-H (1)
PD-L1 deletion + STK11 mutation (1)
PD-L1 elevation + CXCL10 elevation + TNFA elevation (1)
PD-L1 expression + BRAF negative (1)
PD-L1 expression + JAK2 mutation (1)
PD-L1 expression + KMT2D mutation (1)
PD-L1 expression + MSI-H/dMMR (1)
PD-L1 expression + MSI-L/dMMR (1)
PD-L1 expression + PIK3CA mutation (1)
PD-L1 expression + STK11 mutation (1)
PD-L1 expression + STK11 mutation + JAK2 mutation (1)
PD-L1 expression + T-cell gene signature (1)
PD-L1 negative + KRAS G12C (1)
PD-L1 negative + TMB-L (1)
PD-L1 negative + TMB-L + STING overexpression (1)
PD-L1 overexpression + HER-2 exon 20 insertion (1)
PD-L1 overexpression + KRAS G12C + TP53 mutation (1)
PD-L1 overexpression + RET-CCDC6 fusion (1)
PD-L1 overexpression + RET-KIF5B fusion (1)
PD-L1 overexpression + RET-KIF5B fusion + TP53 mutation + AR mutation + RET rearrangement (1)
PD-L1 overexpression + TMB-H (1)
PD-L1 overexpression + TMB-H + ARID1A F2141fs*59 (1)
PD-L1 overexpression + TMB-L (1)
PD-L1 underexpression + EGFR mutation (1)
PD-L1-L (1)
PIK3CA R88Q + PD-L1 expression (1)
POLE mutation + PD-L1 negative + TMB-H (1)
RB1 mutation + PD-L1 expression (1)
RET amplification + TMB-H + PD-L1 expression (1)
ROS1 rearrangement + PD-L1 overexpression (1)
RYR1 mutation + PD-L1 overexpression (1)
SMARCA4 deletion + dMMR/MSI-H + PD-L1 underexpression (1)
SQSTM1-NTRK1 + PIK3CA E545K + TP53 L145R + PD-L1 overexpression (1)
STK11 mutation + TMB-H + PD-L1 overexpression (1)
TERT positive + PD-L1 expression (1)
TMB-H + PD-L1 expression + MSI-L/dMMR (1)
TMB-H + RB1 mutation + PD-L1 underexpression (1)
TMB-L + PD-L1 underexpression (1)
TP53 mutation + MET amplification + PD-L1 overexpression (1)
TP53 mutation + PD-L1 expression (1)
TP53 mutation + PD-L1 negative (1)
TP53 mutation + TMB-H + PD-L1 overexpression (1)
TTF1 expression + NAPSA expression + PD-L1 expression + TMB-H (1)
ARID1A mutation + PD-L1 expression (0)
DDX3X mutation + PD-L1 overexpression (0)
LDHA-H + PD-L1 negative (0)
LDHB-H + PD-L1 negative (0)
NOTCH4 mutation + PD-L1 expression + TMB-H (0)
PD-L1 overexpression + BRAF mutation (0)
PD-L1 underexpression + ALK wild-type (0)
PD-L1 underexpression + EGFR wild-type (0)
PD-L1-H (0)
STAT3 mutation + PD-L1 overexpression (0)
PD-L1 elevation (15)
TMB-H + PD-L1 expression (15)
EGFR mutation + PD-L1 overexpression (8)
TMB-H + PD-L1 overexpression (7)
EGFR exon 19 deletion + PD-L1 overexpression (5)
EGFR mutation + PD-L1 expression (5)
KRAS G12C + PD-L1 overexpression (4)
KRAS mutation + PD-L1 expression (4)
MSI-H/dMMR + PD-L1 expression (4)
PD-L1 expression + EGFR mutation (4)
CD74-ROS1 F2004L + PD-L1 expression (3)
EGFR wild-type + ALK wild-type + PD-L1 expression (3)
MSI-H/dMMR + TMB-H + PD-L1 negative (3)
PD-L1 expression + TMB-H (3)
PD-L1 overexpression + KRAS mutation (3)
ALK rearrangement + PD-L1 overepxression (2)
BRAF V600E + PD-L1 expression (2)
BRAF V600E + PD-L1 expression (2)
EGFR L858R + PD-L1 overexpression (2)
EGFR exon 19 deletion + PD-L1 expression (2)
HER-2 amplification + PD-L1 expression (2)
KRAS G12C + PD-L1 underexpression (2)
KRAS mutation + PD-L1 negative (2)
MSI-H/dMMR + TMB-H + PD-L1 overexpression (2)
PD-1-L + PD-L1 elevation (2)
PD-L1 expression + NRAS Q61R + BRAF D594N (2)
PD-L1 expression + TMB-H + FANCA deletion (2)
PD-L1 overexpression + BRAF V600E (2)
PD-L1 overexpression + EGFR mutation (2)
PD-L1 overexpression + FGFR3 amplification (2)
PD-L1 overexpression + MET exon 14 mutation (2)
RAD51B promoter methylation + PD-L1 expression (2)
TMB-H + PD-L1 negative (2)
TMB-H + PD-L1 underexpression (2)
TMB-L + PD-L1 expression (2)
ALK wild-type + NT5E overexpression + PD-L1 expression (1)
ALK-EML4_V3a + PD-L1 overexpression (1)
ALK-EML4_V3b + PD-L1 overexpression (1)
BAP1 R300Gfs*6 + PD-L1 expression (1)
BAP1 deletion + TMB-L + PD-L1 expression (1)
BRAF E501Q + PD-L1 negative (1)
BRAF V600 + LDH elevation + PD-L1 negative (1)
BRAF mutation + PD-L1 overexpression (1)
BRCA1 mutation + PD-L1 expression (1)
CDKN2A mutation + PD-L1 overexpression (1)
Chr del(9p) + PD-L1 overexpression (1)
DDR + PD-L1 expression (1)
EGFR G719A + EGFR S768I + PD-L1 overexpression (1)
EGFR G719A + PD-L1 overexpression (1)
EGFR L747P + PD-L1 overexpression (1)
EGFR L858R + PD-L1 expression (1)
EGFR L858R + PD-L1 underexpression (1)
EGFR P719A + PD-L1 overexpression (1)
EGFR V843I + KRAS G13D + AKT1 E17K + PD-L1 overexpression (1)
EGFR exon 19 deletion + EGFR T790M + PD-L1 expression (1)
EGFR exon 19 deletion + PD-L1 underexpression (1)
EGFR exon 20 insertion + PD-L1 overexpression (1)
EGFR fusion + PD-L1 overexpression (1)
EGFR mutation + PD-L1 elevation (1)
EGFR mutation + PD-L1 expression + TP53 mutation (1)
EGFR mutation + PD-L1 negative (1)
EGFR negative + ALK negative + PD-L1 expression (1)
EGFR wild-type + ALK wild-type + NT5E overexpression + PD-L1 expression (1)
FGFR mutation + PD-L1 expression (1)
HER-2 exon 20 insertion + TMB-L + PD-L1 negative (1)
HLA-A*02 + PD-L1 expression (1)
HLA-A*02:01 + PD-L1 expression (1)
HRAS Q61R + TP53 P278S + PD-L1 overexpression (1)
KEAP1 mutation + TMB-H + PD-L1 overexpression (1)
KMT2C mutation + BCOR mutation + KDM5C mutation + PD-L1 expression (1)
KRAS G12C + PD-L1 expression (1)
KRAS G12C + PD-L1 underexpression + STK11 mutation (1)
KRAS mutation + PTPN11 overexpression + PD-L1 overexpression (1)
KRAS mutation + PD-L1 underexpression (1)
KRAS mutation + TP53 mutation + PD-L1 expression + PD-1 expression (1)
LDHA-L + PD-L1 expression (1)
LDHB-L + PD-L1 expression (1)
MET exon 14 mutation + MET amplification + PD-L1 overexpression (1)
MGAM mutation + PD-L1 overexpression (1)
PAPPA2 mutation + PD-L1 expression (1)
PD-L1 amplification + CD3D overexpression (1)
PD-L1 amplification + HLA-DRA overexpression (1)
PD-L1 amplification + LAG3 overexpression (1)
PD-L1 amplification + PD-L2 amplification + TMB-H (1)
PD-L1 deletion + STK11 mutation (1)
PD-L1 elevation + CXCL10 elevation + TNFA elevation (1)
PD-L1 expression + BRAF negative (1)
PD-L1 expression + JAK2 mutation (1)
PD-L1 expression + KMT2D mutation (1)
PD-L1 expression + MSI-H/dMMR (1)
PD-L1 expression + MSI-L/dMMR (1)
PD-L1 expression + PIK3CA mutation (1)
PD-L1 expression + STK11 mutation (1)
PD-L1 expression + STK11 mutation + JAK2 mutation (1)
PD-L1 expression + T-cell gene signature (1)
PD-L1 negative + KRAS G12C (1)
PD-L1 negative + TMB-L (1)
PD-L1 negative + TMB-L + STING overexpression (1)
PD-L1 overexpression + HER-2 exon 20 insertion (1)
PD-L1 overexpression + KRAS G12C + TP53 mutation (1)
PD-L1 overexpression + RET-CCDC6 fusion (1)
PD-L1 overexpression + RET-KIF5B fusion (1)
PD-L1 overexpression + RET-KIF5B fusion + TP53 mutation + AR mutation + RET rearrangement (1)
PD-L1 overexpression + TMB-H (1)
PD-L1 overexpression + TMB-H + ARID1A F2141fs*59 (1)
PD-L1 overexpression + TMB-L (1)
PD-L1 underexpression + EGFR mutation (1)
PD-L1-L (1)
PIK3CA R88Q + PD-L1 expression (1)
POLE mutation + PD-L1 negative + TMB-H (1)
RB1 mutation + PD-L1 expression (1)
RET amplification + TMB-H + PD-L1 expression (1)
ROS1 rearrangement + PD-L1 overexpression (1)
RYR1 mutation + PD-L1 overexpression (1)
SMARCA4 deletion + dMMR/MSI-H + PD-L1 underexpression (1)
SQSTM1-NTRK1 + PIK3CA E545K + TP53 L145R + PD-L1 overexpression (1)
STK11 mutation + TMB-H + PD-L1 overexpression (1)
TERT positive + PD-L1 expression (1)
TMB-H + PD-L1 expression + MSI-L/dMMR (1)
TMB-H + RB1 mutation + PD-L1 underexpression (1)
TMB-L + PD-L1 underexpression (1)
TP53 mutation + MET amplification + PD-L1 overexpression (1)
TP53 mutation + PD-L1 expression (1)
TP53 mutation + PD-L1 negative (1)
TP53 mutation + TMB-H + PD-L1 overexpression (1)
TTF1 expression + NAPSA expression + PD-L1 expression + TMB-H (1)
ARID1A mutation + PD-L1 expression (0)
DDX3X mutation + PD-L1 overexpression (0)
LDHA-H + PD-L1 negative (0)
LDHB-H + PD-L1 negative (0)
NOTCH4 mutation + PD-L1 expression + TMB-H (0)
PD-L1 overexpression + BRAF mutation (0)
PD-L1 underexpression + ALK wild-type (0)
PD-L1 underexpression + EGFR wild-type (0)
PD-L1-H (0)
STAT3 mutation + PD-L1 overexpression (0)
›
Associations
(6)
News
Trials
Search handles
@AaronGoodman33
@AndresFCardonaZ
@DocCatenacci
@Dr_R_Kurzrock
@ErikaHamilton9
@Jbauml
@RenoHemonc
@UmutDisel
@antoniomarraMD
@graham74GC
@oncologician
Search handles
@AaronGoodman33
@AndresFCardonaZ
@DocCatenacci
@Dr_R_Kurzrock
@ErikaHamilton9
@Jbauml
@RenoHemonc
@UmutDisel
@antoniomarraMD
@graham74GC
@oncologician
Filter by
Latest
1year
Reed-Sternberg cells (malig cell in Hodgkin) strongly express PDL1 due to amplification of 9p24 which contains the PDL1 & PDL2 locus. An exuberant microenvironment includes plenty of PD1+ T-cells and other immune cells. (fig: Roemer et al, JCO 2018) (@graham74GC)
1 year ago
Immune cell
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • PD-L2 (Programmed Cell Death 1 Ligand 2)
|
PD-L1 expression • PD-L1 amplification
2years
Newly Dx Extra-hepatic BTC - HER2 amplification is X298CN @Aiims1742 @pashtoonkasi PD-L1 amplificationX12CN @Dr_R_Kurzrock @EthanSokol @KlempnerSam @oncologician @GIcancerDoc Tx suggestions ? Chemo plus Anti- HER+- Pembro? (@UmutDisel)
2 years ago
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
|
HER-2 amplification • PD-L1 amplification
|
Keytruda (pembrolizumab)
3years
In hodgkins where PDL1 amplification is assumed, IO is given without checking for TMB . (@RenoHemonc)
3 years ago
PD-L1 (Programmed death ligand 1)
|
PD-L1 amplification
3years
Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors | Cancer Biomarkers | JAMA Oncology | JAMA Network https://t.co/GzKrecMzwC (@Dr_R_Kurzrock)
3 years ago
Checkpoint inhibition • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 amplification
3years
PD-1 blockades doesn't seem to work in DLBCL [Ansell. JCO. 2019.] Perhaps better patient selection like our solid tumor colleagues? High TMB? PD-L1 expression? PD-L1 amplification? PD-L1 translocations? Anything I am missing @Dr_R_Kurzrock (@AaronGoodman33)
3 years ago
Clinical • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
|
PD-L1 expression • TMB-H • PD-L1 amplification
over3years
Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors | Cancer Biomarkers | JAMA Oncology | JAMA Network GoodmAn/KurzrockLab https://t.co/GzKrecMzwC (@Dr_R_Kurzrock)
over 3 years ago
Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 amplification
over3years
Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non–small Cell Lung Cancer https://t.co/ST4MwkMTHc (@AndresFCardonaZ)
over 3 years ago
PD-L1 (Programmed death ligand 1)
|
PD-L1 amplification
|
Opdivo (nivolumab)
over3years
Dual Checkpoint Blockade in a Neuroendocrine Carcinoma With Dual PD-L1/PD-L2 Amplification and High Tumor Mutational Burden - Jco po https://t.co/6n6MY8y5jf (@Dr_R_Kurzrock)
over 3 years ago
Checkpoint inhibition • Tumor Mutational Burden • PD(L)-1 Biomarker
|
TMB (Tumor Mutational Burden) • PD-L2 (Programmed Cell Death 1 Ligand 2)
|
TMB-H • PD-L1 amplification
over3years
Congrats to Natalie Reizine @UCHemOncFellows for showcasing a great story! Complete Response in a Patient With Chemorefractory EGFR-Amplified, PD-L1–Positive Metastatic Gastric Cancer Treated By Dual Anti-EGFR and Anti–PD-1 Monoclonal Antibody Therapy https://t.co/O5MeFh5Xgi (@DocCatenacci)
over 3 years ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
EGFR amplification • PD-L1 amplification
over3years
Metastatic basal cell carcinoma with high TMB and amplification of PD-L1: exceptional response to anti-PD1 therapy - Liver and brain mets. CR 4+ years. Center for Personalized Cancer Therapy https://t.co/N5Wqf6JLAQ (@Dr_R_Kurzrock)
over 3 years ago
PD-L1 (Programmed death ligand 1)
|
PD-L1 amplification
almost4years
The updated ORR and PFS are presented here, noting an increase in ORR. Difference seems amplify with PD-L1 overexpression. Surprising - why should PD-L1 lead to TIGIT working better. I would note that the ORR to atezolizumab alone in this group seems low. #ASCO20 #LCSM (@Jbauml)
almost 4 years ago
PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 overexpression • PD-L1 amplification
|
Tecentriq (atezolizumab)
almost4years
Finally a predictive biomarker for IO in breast cancer -A gain/amplification of CD274 . PD-L1 protein is encoded by gene CD274.Exploratory analyses by Thomas Bachelot at #ESMOBreast20 : mOS in chemo arm -8.8 m Vs NR in durvalumab arm @UmutDisel @FAndreMD (@oncologician)
almost 4 years ago
PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 amplification
|
Imfinzi (durvalumab)
almost4years
PD-L1 gain/amplification as biomarker for #TNBC selection to IO Few patients, but encouraging OS benefit for patients in durvalumab cohort 👉Efficacy of IO also observed in other tumors 👉Can PD-L1 amplification be an agnostic biomarker for IO? @FAndreMD @myESMO @OncoAlert (@antoniomarraMD)
almost 4 years ago
Clinical • PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 amplification
|
Imfinzi (durvalumab)
almost4years
The #overallsurvival spread here according to PDL1/CD274 gain/amplification is impressive. I think we can all agree PDL1 testing alone is likely not the ideal bio marker- this should be examined further. #SAFIR02 #ESMOBreast20 @OncoAlert #bcsm (@ErikaHamilton9)
almost 4 years ago
Clinical • PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 amplification
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login